Loading...
Loading...
RDUS| Name | Value |
|---|---|
| Revenues | 809.6M |
| Cost of Revenue | 713.7M |
| Gross Profit | 95.9M |
| Operating Expense | 68.5M |
| Operating I/L | 27.5M |
| Other Income/Expense | -1.2M |
| Interest Income | 0.0M |
| Pretax | 21.1M |
| Income Tax Expense | 7.2M |
| Net Income/Loss | 13.5M |
Radius Health, Inc. is a biopharmaceutical company specializing in bone health, orphan diseases, and oncology. Its commercial product, TYMLOS, is an abaloparatide injection for treating postmenopausal osteoporosis in women. The company is also developing abaloparatide-SC and abaloparatide-TD for osteoporosis treatment, Elacestrant (RAD1901) for hormone-receptor positive breast cancer, and RAD011 for hyperphagia related to Prader-Willi syndrome. Radius Health, Inc. generates revenue through the sales of TYMLOS and potential future sales of its pipeline products, as well as through collaborations and license agreements with various pharmaceutical companies and institutions.
